Needham analyst Michael Matson maintained a Hold rating on Cantel Medical Corp (NYSE: CMD) today. The company’s shares closed yesterday at $93.61, close to its 52-week low of $88.50.
Matson observed:
“CMD’s F4Q18 revenue and EPS beat consensus. Overall organic revenue growth slowed slightly to 7.5% CC in F4Q18 from 7.6% CC in F3Q18. Organic Endoscopy growth was stable with F3Q18 while organic Water Purification growth slowed from F3Q18. Adjusted gross margin was down 30 bps Y/Y and adjusted operating margin was down 120 bps Y/Y. Importantly, FY19 revenue and EPS (even excluding reinvestments) guidance was below consensus. However, given that CMD shares are well below their all-time high, our view that FY19 is a transition year, and our belief that guidance is conservative, we now have a more positive bias on CMD though we maintain our Hold rating.”
According to TipRanks.com, Matson is a 5-star analyst with an average return of 14.2% and a 65.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Hold analyst consensus rating for Cantel Medical Corp.
See today’s analyst top recommended stocks >>
Cantel Medical Corp’s market cap is currently $3.9B and has a P/E ratio of 42.74. The company has a Price to Book ratio of 6.49.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cantel Medical Corp. engages in the provision, development, and manufacture of infection prevention products and services in the healthcare market. It operates through the following business segments: Endoscopy; Water Purification and Filtration; Healthcare Disposables; Dialysis; and Other.
